Colforsin
Research stageAlso known as Coleonolk, FORSKOLIN, forshkolin, colforsina+2 more
Coleonolk, FORSKOLIN, forshkolin, colforsina, colforsine, colforsinum.
Recent clinical, regulatory, research and industry developments relating to this drug.
cAMP promotes pancreatic beta-cell survival via CREB-mediated induction of IRS2.
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes2
Journals, researchers & institutions
- Genes & development1
- Canettieri G1
- Jhala US1
- Krajewski S1
- Kulkarni RN1
- Lin X1
- Montminy M1
- Reed J1
- Screaton RA1
- The Salk Institute for Biological Studies1
Related drugs
Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).
Studied across 2 of the same disease areas as Colforsin in the shared literature.
Studied across 2 of the same disease areas as Colforsin in the shared literature.
Studied across 2 of the same disease areas as Colforsin in the shared literature.
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- Europe PMC — research literature